How to Group Multiple Models for FDA Registration in the United States?

Core Answer

For multi-model medical device FDA registration, grouping models (Family Grouping) is allowed based on the principle of Substantial Equivalence. Models with the same intended use, same technological characteristics, similar materials and design, and differences that do not affect safety and effectiveness can be grouped into a single product family for a 510(k) submission. The key is to provide a comparison matrix and evidence that the differences do not alter the fundamental safety or performance characteristics.

Applicable Scenarios and Core Issues

When a manufacturer introduces multiple models or variants in the US market, the core question is how to reasonably group them for FDA registration. Grouping reduces the cost and effort of individual submissions but must comply with FDA regulations. It applies to models that are part of the same product line with similar design or performance, such as different sizes of catheters, software version differences, or accessory/material changes. Grouping is not arbitrary; it must demonstrate substantial equivalence in safety and effectiveness. Models with significant differences in intended use, principle of operation, or major technical features cannot be grouped.

Regulatory Decision Logic

Step 1: Confirm whether the product is a medical device subject to FDA regulation. Some products may be classified as drugs, combination products, or non-devices.
Step 2: Determine the classification (Class I, II, or III) to identify the registration pathway. Most Class I devices are exempt from 510(k); Class II requires a 510(k); Class III requires a PMA.
Step 3: For Class II devices requiring 510(k), assess whether multiple models can be submitted as a single product family. FDA uses the “Same or Similar” type grouping: same type means identical design; similar type means design with minor differences.
Step 4: Evaluate if existing technical documentation supports grouping. Prepare a comparison matrix listing key parameters (e.g., dimensions, performance, software version, materials) and analyze the impact of differences on safety and effectiveness.
Step 5: If differences exceed substantial equivalence, models must be registered separately or additional testing data provided.

Required Documentation and Evidence

Grouped submissions require the following core documentation:

• 510(k) Summary or Traditional 510(k) Report: Clearly state the grouping rationale.
• Technical Description: Detailed description of each model, intended use, principle of operation, and key performance metrics.
• Comparison Matrix: Show similarities and differences between all models and the predicate device.
• Performance Test Reports: Electrical safety, mechanical testing, software verification, biocompatibility (ISO 10993) etc., demonstrating performance consistency across models.
• Risk Management Report (ISO 14971): Cover specific risks for each model.
• Clinical Evaluation: If needed, typically literature review or prior device clinical data.
• Labeling: Each model’s label must reflect differences such as model number, specifications, and applicable conditions.
• US Agent Information: A local agent with a US address to communicate with FDA.
• Quality System Certificate: e.g., ISO 13485, or facility registration information.

Common Errors

• Translating NMPA documents directly without restructuring evidence according to the target market pathway.
• Including too many models without adequate test reports, clinical evidence, or labeling coverage.
• Choosing a US agent based solely on sales partnerships without clarifying regulatory responsibilities, certificate control, and post-market obligations.
• Inconsistencies among labels, instructions, promotional materials, and registration documents leading to deficiencies or compliance risks.
• Failing to plan for multi-country documentation reuse, causing repeated work and increased costs.

Preparation Checklist

• Confirm FDA classification and registration pathway (510(k) or PMA).
• Develop a model grouping strategy based on Same/Similar type principles and create a comparison matrix.
• Collect key technical parameters for each model to assess differences.
• Prepare performance verification plans (e.g., electrical safety, EMC, software validation) covering all models.
• Complete a risk management report with analysis for each model.
• Review existing documentation (NMPA, CE, ISO 13485) for grouping support.
• Engage a US agent with a valid US address and execute an agreement.
• Draft the 510(k) submission, emphasizing grouping logic and substantial equivalence evidence.
• Audit labels and instructions to ensure FDA compliance for each model.
• Establish a post-market surveillance system including MDR, recalls, and annual reporting.

AIMEILI Regulatory Interpretation and Business Impact

Many companies misjudge the degree of “similarity” required for grouping. While appearance or functional similarity may seem sufficient, FDA demands substantial equivalence in safety and effectiveness. Early in the project, compile a comprehensive list of model differences and compare with the predicate device to identify models requiring additional testing. Existing NMPA registration data and CE technical files—especially risk management and performance test reports—can be highly reusable but must undergo local conversion, such as adapting clinical evaluations to meet FDA literature review standards.

The US agent is not merely a formal requirement but a critical communication bridge. Choose an experienced agent and ensure control over the certificate. For design changes, assess whether the grouping remains valid. In multi-country registrations, completing US grouping first can streamline subsequent submissions in GHWP member countries (e.g., Japan, Korea, Southeast Asia), reducing duplicate efforts and deficiency risks.

From a business perspective, effective grouping reduces registration costs and time to market. However, inadequate preparation can lead to lengthy review cycles or rejections. Prioritize a unified core technical file and use it as a base for country-specific adaptations.

Frequently Asked Questions

Q1: Will all grouped models share a single 510(k) clearance letter?

Yes. FDA issues one clearance letter for the product family, typically listing all approved models in an attachment. Check the letter to ensure all models are included. For future additions that meet grouping criteria, a Special 510(k) or PMA Supplement (if applicable) can be used.

Q2: If one model in a grouping is denied, does it affect others?

If FDA determines that a specific model does not meet substantial equivalence, it may request splitting the group or submitting additional data. Other models may be temporarily delayed. You can choose to withdraw the problematic model and proceed with the rest. Submit a well-prepared application to avoid such issues.

Q3: Do different models under group registration require separate quality system documentation?

No, but the quality system (e.g., ISO 13485) must cover all manufactured models. Design changes, CAPAs, and risk management records should be traceable to each model. During FDA audits, representative models may be inspected, so ensure consistent coverage across all models.